The latest Business updates from the science industry
by Heather Hobbs Informatics Partnership Provides Continuity across Workfl ows
Scientifi c informatics software and services company Dotmatics has been selected by speciality materials provider Arkema as its informatics partner in an R&D digitalisation project. Under the 5 year agreement, the company’s electronic laboratory notebook (ELN) will be implemented across Arkema’s research sites in France, covering 800 users.
The unifi ed platform will accommodate the diversity of Arkema’s workfl ow across synthetic chemistry, formulation and polymers allowing researchers to trace, share, secure and exploit all their R&D data internally and will facilitate collaboration with external partners.
Steve Gallagher, CEO of Dotmatics, commented: “With our shared spirit of collaboration, we are delighted to have been chosen as a partner to implement their R&D digitalisation project and we welcome Arkema to the Dotmatics community of global scientifi c organisations.
“Implementing Dotmatics’ ELN will allow Arkema researchers to leverage valuable corporate R&D data. Web-based rapid capture, search and retrieval of data combined with advanced analytics will support global shared decision-making, empowering scientists to innovate.”
Gérard Guilpain, Scientifi c Director of Digitalization of R&D at Arkema, said: “The ELN is a fundamental digital building block for processing experimental results generated in our laboratories. We are happy to have selected Dotmatics, which will allow us to modernise our work approaches and use
Steve Gallagher Gérard Guilpain
a cloud infrastructure as a space for digital continuity to gain value more rapidly from the Group’s research data.”
Further information online:
ilmt.co/PL/VqkQ 55164pr@reply-direct.com
Investors Back Spinout’s Therapy Developments for SNHL
University of Sheffi eld spinout company, Rinri Therapeutics, has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund, to support the development of its novel stem cell therapy to treat sensorineural hearing loss (SNHL).
The company’s underlying technology is based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffi eld. It seeks to reverse SNHL through the repair of the damaged cytoarchitecture in the inner ear.
SNHL happens when there is damage to the hair cells in the cochlea and/ or to the auditory nerve. There are currently no pharmacological treatments available for SNHL despite the increasing number of patients that suffer from this condition globally.
Professor Marcelo Rivolta, said: “This investment is a validation of the journey we started several years ago. We are very happy and grateful for the continued support from our investors, now together with the UK Future Fund. We believe the technology we are developing can have a substantial impact on the lives of people affected by hearing loss, and these funds will help us pave the way to a fi rst in man clinical trial.”
Dr Simon Chandler, CEO of Rinri Therapeutics, commented: “We are very pleased to receive continuing support from existing investors alongside matched funding from the UK Future Fund. Our major investors share the vision we have for our technology to bring transformational changes to the lives of patients suffering from hearing loss, and the proceeds from this fund raising will allow us to advance our pioneering journey towards fi rst in-man clinical trials and to ultimately realise the potential of stem cell therapy to reverse sensorineural hearing loss.”
Frank Kalkbrenner, Global Head of the Boehringer Ingelheim Venture Fund, said: “We are delighted to continue our backing of Rinri and its pioneering approach to hearing loss, now with the added endorsement and support of the Future Fund. We believe Rinri’s’ technology is differentiated from other approaches to hearing loss restoration and has the potential to make a signifi cant impact on treatment.”
More information online:
ilmt.co/PL/Dzom 55178pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196
